104 related articles for article (PubMed ID: 19631836)
1. [Implications of the REACH registry for neurologists].
Roquer J
Med Clin (Barc); 2009 Sep; 132 Suppl 2():30-3. PubMed ID: 19631836
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic analysis: results of the REACH registry].
Suárez C; Abadía C; Echevarria A
Med Clin (Barc); 2009 Sep; 132 Suppl 2():41-3. PubMed ID: 19631839
[TBL] [Abstract][Full Text] [Related]
3. [One-year data from the REACH registry in Spain].
Suárez C; Polo IG; Ibáñez P
Med Clin (Barc); 2009 Sep; 132 Suppl 2():10-4. PubMed ID: 19631832
[TBL] [Abstract][Full Text] [Related]
4. [The REACH registry: baseline and 1-year results].
Esmatjes E; Blanco AJ
Med Clin (Barc); 2009 Sep; 132 Suppl 2():5-9. PubMed ID: 19631831
[TBL] [Abstract][Full Text] [Related]
5. [Implications of the REACH registry for cardiologists].
de la Villa Redondo BG
Med Clin (Barc); 2009 Sep; 132 Suppl 2():15-20. PubMed ID: 19631833
[TBL] [Abstract][Full Text] [Related]
6. [Implications of the REACH registry for endocrinologists].
Alonso G
Med Clin (Barc); 2009 Sep; 132 Suppl 2():21-4. PubMed ID: 19631834
[TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics of patients with cerebrovascular disease in the REACH registry: the Spanish contribution.
Suárez C;
Cerebrovasc Dis; 2007; 24 Suppl 1():89-95. PubMed ID: 17971643
[TBL] [Abstract][Full Text] [Related]
8. [Use of drugs in the REACH registry: from guidelines to clinical practice].
Gómez Cerezo JF
Med Clin (Barc); 2009 Sep; 132 Suppl 2():44-6. PubMed ID: 19631840
[TBL] [Abstract][Full Text] [Related]
9. [Implications of the REACH registry for internal medicine].
Ramos Salado JL
Med Clin (Barc); 2009 Sep; 132 Suppl 2():34-7. PubMed ID: 19631837
[TBL] [Abstract][Full Text] [Related]
10. [Implications of the REACH registry for vascular surgery].
Alvarez-Fernández LJ; Vallina-Victorero Vázquez MJ; Ramos Gallo MJ; Santiago MV
Med Clin (Barc); 2009 Sep; 132 Suppl 2():25-9. PubMed ID: 19631835
[TBL] [Abstract][Full Text] [Related]
11. The burden of peripheral artery disease and the role of antiplatelet therapy.
Aronow H; Hiatt WR
Postgrad Med; 2009 Jul; 121(4):123-35. PubMed ID: 19641278
[TBL] [Abstract][Full Text] [Related]
12. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics.
Bushnell C; Zimmer L; Schwamm L; Goldstein LB; Clapp-Channing N; Harding T; Drew L; Zhao X; Peterson E;
Am Heart J; 2009 Mar; 157(3):428-435.e2. PubMed ID: 19249411
[TBL] [Abstract][Full Text] [Related]
13. [Optimizing overall risk reduction: implications of the REACH registry. Introduction].
Steg G
Med Clin (Barc); 2009 Sep; 132 Suppl 2():1. PubMed ID: 19798791
[No Abstract] [Full Text] [Related]
14. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis.
Reid CM; Ademi Z; Nelson MR; Connor G; Chew DP; Shiel L; Smeath A; De Looze F; Steg PG; Bhatt DL; Liew D;
Med J Aust; 2012 Feb; 196(3):193-7. PubMed ID: 22339526
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after stroke: risk of recurrent ischemic stroke and other events.
Elkind MS
Am J Med; 2009 Apr; 122(4 Suppl 2):S7-13. PubMed ID: 19332241
[TBL] [Abstract][Full Text] [Related]
16. [Compliance with the measures for preventing vascular risk factors in hospitalised patients with acute stroke. Analysis of a national multi-centre registry: EPICES registry (III)].
Blanco M; Vivancos-Mora J; Castillo J;
Rev Neurol; 2012 May; 54(9):523-9. PubMed ID: 22532215
[TBL] [Abstract][Full Text] [Related]
17. [Atherothrombosis: an excessively globalizing concept?].
Castillo J; Blanco M
Med Clin (Barc); 2009 Sep; 132 Suppl 2():2-4. PubMed ID: 19631830
[TBL] [Abstract][Full Text] [Related]
18. Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long enough?
Lip GY; Krishnamoorthy S
Hamostaseologie; 2009 Jan; 29(1):96-101. PubMed ID: 19151857
[TBL] [Abstract][Full Text] [Related]
19. The protective effect of risk factors against stroke severity.
Steiner I; Gotkine M; Wirguin I
J Neurol Sci; 2008 Apr; 267(1-2):187-8. PubMed ID: 18068188
[No Abstract] [Full Text] [Related]
20. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
